ClaimAstraZeneca and Ionis' Wainua (eplontersen) Phase III CARDIO-TTRansform trial failed to meet its primary efficacy endpoint in transthyretin-mediated amyloid cardiomyopathy (ATTR-CM).

ClaimKeenova Therapeutics' Xiaflex met its primary endpoint in the Phase III STRIDE study, demonstrating statistically significant improvement in pain for patients with plantar fibromatosis.

ClaimDysport (abobotulinumtoxinA) is the first botulinum toxin to demonstrate statistically significant efficacy in preventing both episodic and chronic migraine in Phase III trials.

ClaimRoche has discontinued the clinical development of tominersen and RG6496 for Huntington's disease due to a lack of efficacy in a Phase 2 trial and a safety signal in animal testing, respectively.

ClaimMAIA Biotechnology's ateganosine, in combination with cemiplimab, achieved a 90.5% disease control rate in heavily pre-treated advanced non-small cell lung cancer patients in its Phase II THIO-101 Part C study.

ClaimCompass Pathways' psilocybin treatment COMP360 demonstrated durable efficacy in patients with treatment-resistant depression, maintaining clinically meaningful responses through 26 weeks in a Phase 3 trial.

ClaimBristol Myers Squibb's Krazati, in combination with cetuximab, failed to significantly improve overall and progression-free survival in the Phase 3 KRYSTAL-10 study for metastatic colorectal cancer patients with the G12C KRAS mutation.

ClaimTeva Pharmaceutical Industries Ltd. announced plans to advance its investigational anti-interleukin-15 monoclonal antibody, TEV-’408, into a Phase 2b study for vitiligo in Q4 2026, following encouraging Phase 1b results showing improvements in skin pigmentation and a favorable safety profile.

ClaimAnixa Biosciences has treated the first patient in the fifth and highest dose cohort of its Phase I trial for lira-cel in recurrent ovarian cancer, observing no dose-limiting toxicities and encouraging survival signals.

ClaimIonis Pharmaceuticals has completed enrolment for the pivotal cohort of its Phase III REVEAL study of obudanersen for Angelman syndrome.

ClaimNextBiomedical's Nexsphere-F device significantly reduced knee osteoarthritis pain by a mean of 57% in a European clinical study, moving closer to becoming a standard of care.

ClaimAgenus's combination therapy of botensilimab and balstilimab demonstrated a 33% three-year overall survival rate and a median overall survival of 21.2 months in heavily pretreated patients with refractory microsatellite-stable metastatic colorectal cancer.

ClaimMoleculin's CEO discussed positive preliminary unblinded efficacy results from the first 45 patients in Part A of the pivotal Phase 2/3 MIRACLE trial evaluating Annamycin in relapsed or refractory acute myeloid leukemia.

ClaimBridgeBio's Attruby demonstrated sustained and significant kidney-protective effects in patients with transthyretin amyloidosis cardiomyopathy, differentiating it from competitors.

ClaimMolecular Partners and Orano Med have dosed the first patient in a Phase I/IIa trial for MP0712, a DLL3-targeting radio-DARPin for small cell lung cancer.

ClaimBrii Biosciences reported topline end-of-treatment data from its Phase IIb ENRICH and ENHANCE trials, showing promising HBsAg loss rates for BRII-179-based regimens in chronic hepatitis B virus infection.

ClaimThe MS-DETECT study demonstrated that the MS Copilot Detect smartphone app effectively monitors multiple sclerosis disease progression and its scores correlated with the MSFC-4 framework over 12 months.

ClaimVamorolone demonstrated balanced corticosteroid activity, achieving expected cortisol suppression and anti-inflammatory effects without significant immunosuppressive activity at clinical doses in a Phase 1 study.

ClaimTransCon CNP demonstrated continued improvements in lower extremity alignment, specifically a mean absolute change of -2.2 degrees in tibial-femoral angle (TFA), in children with achondroplasia over two years of treatment.

ClaimA fixed-duration combination of Epkinly (epcoritamab) and Revlimid (lenalidomide) significantly improved progression-free survival and reduced the risk of disease progression and death by 60% in the US and 56% outside the US in adult patients with relapsed or refractory diffuse large B-cell lymphoma.

ClaimEvommune halted the development of its lead asset, EVO756, for chronic spontaneous urticaria after its Phase 2b study failed to show significant benefit across all tested doses.

ClaimAnnamycin, combined with HiDAC, demonstrated higher complete remission rates (43% and 36%) compared to the HiDAC control arm (12%) in relapsed or refractory acute myeloid leukemia patients.

ClaimRegeneron's Phase III NIMBLE study demonstrated that cemdisiran monotherapy significantly improved Myasthenia Gravis-Activities of Daily Living (MG-ADL) at week 24 in generalized myasthenia gravis patients, meeting its primary endpoint.

ClaimSkyhawk Therapeutics' oral drug, SKY-0515, for Huntington's disease demonstrated favorable trends in functional and motor scores, dose-dependent reductions in mutant huntingtin protein, and an extraordinary safety profile in a Phase 1/2 trial.

ClaimNatera and Aveta Biomics have partnered to initiate a global Phase III clinical trial (AVTA 30-01) assessing APG-157, an oral immunotherapy, in patients with locally advanced head and neck squamous cell carcinoma.

ClaimNeuroSense Therapeutics' combination ALS therapy, PrimeC, demonstrated a statistically significant reduction in TDP-43 protein levels in its Phase IIb PARADIGM study, meeting the primary endpoint.

ClaimEvommune terminated development of its oral MRGPRX2 antagonist, EVO756, for chronic spontaneous urticaria after it failed to meet its primary endpoint in a Phase IIb study.

ClaimBridgeBio Pharma's oral drug, infigratinib, demonstrated significant improvements in growth velocity and body proportionality, including a 2.1-cm/year advantage in annualized growth velocity, in children with achondroplasia during the Phase 3 PROPEL 3 study.

ClaimThe Harmoni-3 trial aims to demonstrate that ivonescimab plus chemotherapy is superior to Keytruda plus chemotherapy in delaying disease progression and death for frontline non-small cell lung cancer.

ClaimGSK's mocertatug rezetecan achieved a confirmed objective response rate of 62% in platinum-resistant ovarian cancers and 67% in endometrial cancer in its Phase 1 trial.

ClaimCorxel Pharmaceuticals' oral GLP-1RA candidate, CX11, demonstrated up to 11.5% weight loss over 36 weeks with a favorable gastrointestinal tolerability and safety profile in Phase II trials for obese or overweight adults.

ClaimDefinium Therapeutics' LSD formulation demonstrated significant efficacy over placebo in relieving symptoms of major depression in late-stage trial data.

ClaimADC Therapeutics' Zynlonta plus rituximab failed to demonstrate an overall survival benefit in the LOTIS-5 Phase 3 trial for relapsed or refractory diffuse large B cell lymphoma.

ClaimMSD's investigational humanised monoclonal antibody, tulisokibart, successfully met all primary and key secondary endpoints in its Phase III ATLAS-UC induction-only study, demonstrating significant improvements and clinical remission at week 12 in patients with moderately to severely active ulcerative colitis.

ClaimPORT-77 demonstrated a mean 79% decrease in plasma protoporphyrin IX (PPIX) at the 300mg BID dose and was well tolerated in the Phase IIa GATEWAY study for erythropoietic protoporphyria (EPP) and X-linked protoporphyria (XLP).

ClaimMerck's investigational antibody, tulisokibart, successfully met its primary endpoint of clinical remission at 12 weeks in a late-stage study for ulcerative colitis.

ClaimPhathom Pharmaceuticals has completed patient enrollment in its Phase 2 pHalcon-EoE-201 clinical trial evaluating VOQUEZNA (vonoprazan) for eosinophilic esophagitis (EoE) in adults.

ClaimElevar Therapeutics has initiated its global Phase 2 ReFocus202 study of lirafugratinib in non-cholangiocarcinoma solid tumors characterized by FGFR2 fusion or rearrangement.

ClaimMerck & Co.'s experimental drug, tulisokibart, successfully met its primary goal in a Phase 3 study for moderately to severely active ulcerative colitis.

ClaimDefinium Therapeutics' oral psychedelic treatment, DT120, achieved all primary and secondary endpoints in its Phase 3 Emerge trial for major depressive disorder, demonstrating an 8.1-point placebo-adjusted change on the MADRS at six weeks.

ClaimuniQure's investigational gene therapy, AMT-260, demonstrated a significant 79% to 100% reduction in disabling seizures in three out of six patients in the low-dose cohort of the Phase 1/2a GenTLE trial for refractory mesial temporal lobe epilepsy.

ClaimThe UK's MHRA and HRA have approved the continuation of the Phase III PATHWAYS trial investigating puberty blockers for children and young people with gender incongruence, under a modified protocol with strengthened safeguards.

ClaimOlorofim demonstrated non-inferiority to AmBisome followed by standard of care in all-cause mortality at day 42 for adults with invasive aspergillosis, with a favorable safety profile.

ClaimEDG-7500, a cardiac sarcomere modulator, demonstrated positive top-line data in the Phase II CIRRUS-HCM trial, showing broad clinical responses and good tolerability in patients with obstructive and non-obstructive hypertrophic cardiomyopathy.

ClaimGelteq Limited completed planning for a human clinical trial, launched a veterinary antiparasitic trial, and initiated a preclinical diabetes study in the first half of 2026.

ClaimElicio Therapeutics reported preliminary clinical observations of complete radiographic and metabolic responses in three metastatic mKRAS pancreatic cancer patients previously treated with ELI-002 7P and subsequent nivolumab-based therapy.

ClaimBe Biopharma terminated its Phase 1/2 BeCoMe-9 study for BE-101, an autologous B cell therapy for hemophilia B, due to a strategic business decision.

ClaimThe Phase III MonumenTAL-3 trial demonstrated a profound progression-free survival benefit for Talvey plus Darzalex and pomalidomide (Tal-DP) and Talvey plus daratumumab (Tal-D) regimens in relapsed or refractory multiple myeloma, with hazard ratios of 0.28 and 0.33 respectively.

ClaimThe all-oral combination of Beqalzi and Brukinsa achieved a 100% overall response rate and 100% 24-month progression-free survival with a favorable safety profile as a first-line treatment for chronic lymphocytic leukemia or small lymphocytic lymphoma.

ClaimJaypirca (pirtobrutinib) combined with venetoclax and rituximab reduced the risk of disease progression or death by 45% in patients with relapsed or refractory chronic lymphocytic leukaemia or small lymphocytic lymphoma.